Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy
NCT ID: NCT01382498
Last Updated: 2011-06-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
90 participants
INTERVENTIONAL
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy
NCT02388984
Using Calcium Dobesilate to Treat Chinese Patients With Mild to Moderate Non-proliferative Diabetic Retinopathy
NCT04283162
Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients
NCT02099981
A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema
NCT01506895
Pharmacological Intervention in Diabetic Retinopathy
NCT00619034
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo tablets will be administered to the patients in Placebo arms daily for three months.
Placebo drug
Similar to the that of the Experimental arm, Daily, Three months
Calcium dobesilate
Calcium dobesilate as 500 mg tablets will be administered once to the patients daily.
Calcium dobesilate (Doxium)
500 mg, Tablet, Daily, 3 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Calcium dobesilate (Doxium)
500 mg, Tablet, Daily, 3 months
Placebo drug
Similar to the that of the Experimental arm, Daily, Three months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 40-70
* Severe NPDR(non proliferative diabetic retinopathy) or PDR(proliferative diabetic retinopathy)
* type II diabetes
* no history of doxium consumption
Exclusion Criteria
* incidence of active hepatic disease or rising of hepatic enzymes during the intervention
40 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tabriz University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tabriz University of Medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tabriz University of Medical Sciences
Tabriz, Eastern Azerbayjan, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
88-8
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.